MedTrace Logo

Assessing Tolerability of Avonex Intramuscular Injections

NCT01641120 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-02-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate patients' views when injecting Avonex intramuscularly.

Conditions

Interventions

DRUG

Avonex

Intramuscular injection administered using 25 gauge or 30 gauge needle

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Trinity Health Of New England

    lead OTHER

Principal Investigators

  • Peter B Wade, MD · Mandell Center for Multiple Sclerosis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01641120 on ClinicalTrials.gov